Dominantly Inherited Alzheimer Network (DIAN)
ConditionAlzheimer's Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWashington University School of Medicine
About this trial
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Written informed consent obtained from participant and collateral source prior to any study-related procedures.
Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD.
Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.
Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study.
Disqualifiers
Under age 18
Medical or psychiatric illness that would interfere in completing initial and follow-up visits
Requires nursing home level care
Has no one who can serve as a study informant
Trial population
Mutation carriers and non-carriers from families with a mutation (which is different from the genetic risk factor Apo-E4) known to cause Alzheimer's disease.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
700 Participants
are grouped into 2 trial groupsGroup A: 1
Group B: 2
Trial outcomes
Primary outcomes
1
Positive predictive power of a biomarker or group of biomarkers
Time frame
Variable follow-up assessment based on age in relation to age at onset of affected parent.2
Biomarkers obtained by blood draw, lumbar puncture, MRI, FDG PET, PET amyloid imaging
Time frame
Variable follow-up assessment based on age in relation to age at onset of affected parent3
Clinical markers also examined from clinical interview and cognitive testing
Time frame
Variable follow-up assessment based on age in relation to age at onset of affected parentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Washington University School of Medicine
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov